Login to Your Account



Bluebird brightens Lentiglobin outlook with protocol, manufacturing changes

By Michael Fitzhugh
Staff Writer

Wednesday, November 1, 2017

Bluebird Bio Inc. reported that new data from an ongoing phase I trial of its gene therapy, Lentiglobin, in sickle cell disease suggests that changes made to the study protocol and to manufacturing of the therapy are improving engraftment of the gene-modified stem cells.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription